AB PT cmplx conc kcentra lab
Ended Awarded Last action
- Contract number
- SPE2DR26FHNU4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,244
Award facts
- Contract value 100% obligated
- $3,243.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) issued a delivery order valued at $3,243.68 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the delivery of pharmaceutical products and medical consumables. This delivery order, issued on January 12, 2026, with an ultimate completion date of February 3, 2026, was awarded on a firm fixed-price basis with no set-aside designation, indicating the contractor competed in unrestricted federal procurement. The delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy established to supply diverse pharmaceutical needs across Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group holds a single-award IDC under PPV-G GEN V designated as contract SPE2DR, awarded November 13, 2025, with a $500 million ceiling value and completion date of December 31, 2036. The contract includes a 30-month base period with three 30-month option periods and authorizes DLA to issue delivery orders for branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and medical consumables to support military healthcare operations globally. The company's established performance record supplying specialized pharmaceuticals including oncology treatments, immunosuppressants, biologics, emergency medications, and surgical products demonstrates its capability as a critical regional pharmaceutical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FHNU4?
SPE2DR26FHNU4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FHNU4 worth?
The government has obligated $3,244 on SPE2DR26FHNU4.
Is contract SPE2DR26FHNU4 an order under another contract?
Yes. SPE2DR26FHNU4 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNU4 competed?
The extent of competition for SPE2DR26FHNU4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award